NCT07044427

Brief Summary

Approximately one third of the population over the age of 65 falls at least once a year. The risk of falling is in increased in older patients with tumor diseases. In addition to high treatment and care costs for the healthcare system, falls often lead to a decrease of quality of life, a reduction in physical performance and a loss of independence. Despite the high risk, falls in cancer patients have not yet been scientifically investigated in detail. For patients with multiple myeloma in particular, very little data is available on the prevalence, risk factors and effects of falls. In this study, a fall risk assessment is carried out in patients with multiple myeloma. Furthermore, a patient-specific training intervention for fall prevention will be implemented. The aim of the study is to identify possible fall risk factors in multiple myeloma patients and to establish a structured exercise intervention that minimizes the risk of falls and injuries.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable multiple-myeloma

Timeline
7mo left

Started Feb 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress78%
Feb 2024Dec 2026

Study Start

First participant enrolled

February 2, 2024

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 10, 2025

Completed
21 days until next milestone

First Posted

Study publicly available on registry

July 1, 2025

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2026

Last Updated

January 22, 2026

Status Verified

January 1, 2026

Enrollment Period

2.9 years

First QC Date

June 10, 2025

Last Update Submit

January 19, 2026

Conditions

Keywords

Multiple MyelomaFall riskpertubation trainingstrength trainingBalance

Outcome Measures

Primary Outcomes (2)

  • Feasibility of at least 48 out of 72 training sessions with the focus on fall prevention within 24 weeks

    Patients will document the number of training sessions via an online training-app (Physiotec, Bad Wünnenberg, Germany). Feasibility is achieved if 48 of 72 possible training sessions were successfully completed.

    From enrollement to the end of the training intervention at 6 months

  • Effectivity (fear of falling)

    Fear of falling will be evaluated by a validated questionnaire (FES-I, Falls Efficacy Scale-Inernational). The questionnaire contains 16 items scored on a four-point scale (1=not at all concerned to 4=very concerned). Scores \>23 indicate high concern about falling.

    Evaluated at the beginning of the study and at the end of the study after 6 months

Study Arms (1)

Exercise Intervention

OTHER

Fall Prevention

Other: Strength and balance training in combination with a treadmill-based pertubation intervention

Interventions

Patients receive a personalized home-based training plan with strength and balance exercises to be carried out three times a week for six months. In addition, treadmill-based pertubation training is carried out at 2 timepoints.

Exercise Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with multiple myeloma requiring therapy (at least 6 months of systemic therapy)
  • ECOG status ≤ 3
  • Age ≥18 years
  • Patients who state that they want to carry out the training program at least 3 times/week and participate in the planned follow-up visits
  • Ability to give informed consent
  • Written consent to participate in the study
  • Sufficient written and spoken German to complete the questionnaire

You may not qualify if:

  • Any physical or mental limitations that would prevent participation in the training program or the planned follow-up checks.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Heidelberg

Heidelberg, Baden Würtemberg, 69120, Germany

RECRUITING

Related Publications (5)

  • Wildes TM, Fiala MA. Falls in older adults with multiple myeloma. Eur J Haematol. 2018 Mar;100(3):273-278. doi: 10.1111/ejh.13009. Epub 2018 Jan 8.

    PMID: 29239009BACKGROUND
  • Wildes TM, Dua P, Fowler SA, Miller JP, Carpenter CR, Avidan MS, Stark S. Systematic review of falls in older adults with cancer. J Geriatr Oncol. 2015 Jan;6(1):70-83. doi: 10.1016/j.jgo.2014.10.003. Epub 2014 Oct 30.

    PMID: 25454770BACKGROUND
  • Dapunt U, Ehret P, Paratte JL, Kuehl RM, Wiskemann J, Jager D, Muller-Tidow C, Raab MS, Goldschmidt H. A precision-based exercise program for patients with multiple myeloma. Eur J Haematol. 2023 Dec;111(6):930-937. doi: 10.1111/ejh.14106. Epub 2023 Sep 20.

    PMID: 37727991BACKGROUND
  • Sattar S, Alibhai SM, Spoelstra SL, Fazelzad R, Puts MT. Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment. Support Care Cancer. 2016 Oct;24(10):4459-69. doi: 10.1007/s00520-016-3342-8. Epub 2016 Jul 22.

    PMID: 27450557BACKGROUND
  • Pandya C, Magnuson A, Dale W, Lowenstein L, Fung C, Mohile SG. Association of falls with health-related quality of life (HRQOL) in older cancer survivors: A population based study. J Geriatr Oncol. 2016 May;7(3):201-10. doi: 10.1016/j.jgo.2016.01.007. Epub 2016 Feb 18.

    PMID: 26907564BACKGROUND

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Dapunt

    University Hospital Heidelberg

    STUDY CHAIR

Central Study Contacts

Ulrike Dapunt, prof. Dr. med

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. med.

Study Record Dates

First Submitted

June 10, 2025

First Posted

July 1, 2025

Study Start

February 2, 2024

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

December 30, 2026

Last Updated

January 22, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

* questionnaire results collected for each individual * functional test results collected for each individual

Locations